While the development of PARP inhibitors (discussed in next section) removes some incentive to therapeutically target XRCC1, this protein clearly represents an important predictive factor for cancer risk and platinum-based therapeutics in PDA (Figure 4). This evidence concerns the gene XRCC1 and Patent ductus arteriosus.